Ironwood Pharmaceuticals Stock Performance
| IRWD Stock | USD 4.49 0.30 6.26% |
Ironwood Pharmaceuticals holds a performance score of 17 on a scale of zero to a hundred. The company retains a Market Volatility (i.e., Beta) of 2.63, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Ironwood Pharmaceuticals will likely underperform. Use Ironwood Pharmaceuticals maximum drawdown, as well as the relationship between the expected short fall and rate of daily change , to analyze future returns on Ironwood Pharmaceuticals.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Ironwood Pharmaceuticals are ranked lower than 17 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, Ironwood Pharmaceuticals exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (6.37) | Five Day Return (6.76) | Year To Date Return 5.04 | Ten Year Return (50.61) | All Time Return (61.50) |
Last Split Factor 1194:1000 | Last Split Date 2019-04-02 |
1 | Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results Raises Full Year 2025 Financial Guidance | 11/10/2025 |
2 | Ironwood Pharmaceuticals Shares Gap Up Still a Buy | 11/26/2025 |
3 | Acquisition by Denner Alexander J of 4178 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 | 12/15/2025 |
4 | Ironwood Pharmaceuticals, Inc. Receives Average Recommendation of Hold from Brokerages - MarketBeat | 12/17/2025 |
5 | Ironwood Pharma Stock Rallies On Strong 2026 Outlook | 01/02/2026 |
6 | Disposition of 35416 shares by Ronald Silver of Ironwood Pharmaceuticals at 4.6 subject to Rule 16b-3 | 01/05/2026 |
7 | Why Ironwood Pharmaceuticals Is Up 37.8 percent After New 2026 Guidance And Ferring Settlement | 01/06/2026 |
8 | Ironwood Pharma resolves Ferring dispute, amends license terms - MSN | 01/09/2026 |
9 | Acquisition by Dreyfus Andrew of 24311 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 | 01/16/2026 |
10 | Zacks Research Has Positive Outlook for IRWD Q4 Earnings | 01/21/2026 |
11 | Ironwood Pharmaceuticals Inc Fits the Minervini High-Growth Momentum Trend Template - Chartmill | 01/30/2026 |
12 | Acquisition by John Minardo of 122222 shares of Ironwood Pharmaceuticals subject to Rule 16b-3 | 02/03/2026 |
13 | Craig-Hallum Bullish on Ironwood Pharmaceuticals , Keeps Buy Rating | 02/04/2026 |
| Begin Period Cash Flow | 92.2 M | |
| Total Cashflows From Investing Activities | -142 K |
Ironwood Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 192.00 in Ironwood Pharmaceuticals on November 7, 2025 and sell it today you would earn a total of 257.00 from holding Ironwood Pharmaceuticals or generate 133.85% return on investment over 90 days. Ironwood Pharmaceuticals is currently generating 1.6846% in daily expected returns and assumes 7.6432% risk (volatility on return distribution) over the 90 days horizon. In different words, 68% of stocks are less volatile than Ironwood, and 67% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Ironwood Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Ironwood Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.49 | 90 days | 4.49 | about 18.32 |
Based on a normal probability distribution, the odds of Ironwood Pharmaceuticals to move above the current price in 90 days from now is about 18.32 (This Ironwood Pharmaceuticals probability density function shows the probability of Ironwood Stock to fall within a particular range of prices over 90 days) .
Ironwood Pharmaceuticals Price Density |
| Price |
Predictive Modules for Ironwood Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Ironwood Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Ironwood Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Ironwood Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Ironwood Pharmaceuticals is not an exception. The market had few large corrections towards the Ironwood Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Ironwood Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Ironwood Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 1.81 | |
β | Beta against Dow Jones | 2.63 | |
σ | Overall volatility | 0.93 | |
Ir | Information ratio | 0.23 |
Ironwood Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Ironwood Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Ironwood Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Ironwood Pharmaceuticals is way too risky over 90 days horizon | |
| Ironwood Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from insidermonkey.com: Craig-Hallum Bullish on Ironwood Pharmaceuticals , Keeps Buy Rating |
Ironwood Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Ironwood Stock often depends not only on the future outlook of the current and potential Ironwood Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Ironwood Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 160.1 M | |
| Cash And Short Term Investments | 88.6 M |
Ironwood Pharmaceuticals Fundamentals Growth
Ironwood Stock prices reflect investors' perceptions of the future prospects and financial health of Ironwood Pharmaceuticals, and Ironwood Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Ironwood Stock performance.
| Return On Equity | -5.75 | ||||
| Return On Asset | 0.23 | ||||
| Profit Margin | 0.08 % | ||||
| Operating Margin | 0.64 % | ||||
| Current Valuation | 1.26 B | ||||
| Shares Outstanding | 162.68 M | ||||
| Price To Earning | 18.35 X | ||||
| Price To Book | 2.59 X | ||||
| Price To Sales | 2.30 X | ||||
| Revenue | 351.41 M | ||||
| Gross Profit | 344.19 M | ||||
| EBITDA | 97.73 M | ||||
| Net Income | 880 K | ||||
| Cash And Equivalents | 504.36 M | ||||
| Cash Per Share | 3.29 X | ||||
| Total Debt | 599.48 M | ||||
| Debt To Equity | 0.78 % | ||||
| Current Ratio | 26.52 X | ||||
| Book Value Per Share | (1.62) X | ||||
| Cash Flow From Operations | 103.55 M | ||||
| Earnings Per Share | 0.18 X | ||||
| Market Capitalization | 779.23 M | ||||
| Total Asset | 350.91 M | ||||
| Retained Earnings | (1.7 B) | ||||
| Working Capital | 143.52 M | ||||
| Current Asset | 500.2 M | ||||
| Current Liabilities | 76.47 M | ||||
About Ironwood Pharmaceuticals Performance
By analyzing Ironwood Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Ironwood Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Ironwood Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Ironwood Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 370.02 | 671.81 | |
| Return On Capital Employed | 0.34 | 0.36 |
Things to note about Ironwood Pharmaceuticals performance evaluation
Checking the ongoing alerts about Ironwood Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Ironwood Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Ironwood Pharmaceuticals is way too risky over 90 days horizon | |
| Ironwood Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Over 92.0% of the company shares are owned by institutional investors | |
| Latest headline from insidermonkey.com: Craig-Hallum Bullish on Ironwood Pharmaceuticals , Keeps Buy Rating |
- Analyzing Ironwood Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Ironwood Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Ironwood Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Ironwood Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Ironwood Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Ironwood Pharmaceuticals' stock. These opinions can provide insight into Ironwood Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Stocks Directory Find actively traded stocks across global markets | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |